Cite
Kaminska K, Akrap N, Staaf J, et al. Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer. Breast Cancer Res. 2021;23(1):26doi: 10.1186/s13058-021-01402-1.
Kaminska, K., Akrap, N., Staaf, J., Alves, C. L., Ehinger, A., Ebbesson, A., Hedenfalk, I., Beumers, L., Veerla, S., Harbst, K., Ehmsen, S., Borgquist, S., Borg, �. �., Pérez-Fidalgo, A., Ditzel, H. J., Bosch, A., & Honeth, G. (2021). Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer. Breast cancer research : BCR, 23(1), 26. https://doi.org/10.1186/s13058-021-01402-1
Kaminska, Kamila, et al. "Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer." Breast cancer research : BCR vol. 23,1 (2021): 26. doi: https://doi.org/10.1186/s13058-021-01402-1
Kaminska K, Akrap N, Staaf J, Alves CL, Ehinger A, Ebbesson A, Hedenfalk I, Beumers L, Veerla S, Harbst K, Ehmsen S, Borgquist S, Borg Å, Pérez-Fidalgo A, Ditzel HJ, Bosch A, Honeth G. Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer. Breast Cancer Res. 2021 Feb 18;23(1):26. doi: 10.1186/s13058-021-01402-1. PMID: 33602273; PMCID: PMC7893923.
Copy
Download .nbib